Virtue Diagnostics and Revvity Ink Exclusive Global Distribution Agreement
Date: 2023-12-13
On December 13, 2023, Suzhou Virtue Diagnostics Co., Ltd. (hereinafter referred to as “Virtue Diagnostics”) and Revvity,Inc (hereinafter referred to as “Revvity”) signed a global exclusive distribution agreement for 3 Revvity product lines: Time-Resolved Fluorescence (TRF) Immunoassay Platform, PCR Molecular diagnostics analyzer for infectious disease diagnosis (Pre-Nat II nucleic acid extraction system), and chemiluminescence Point-of-Care Testing analyzer (POCT analyzer) for cardiac and inflammation markers (SuperFlex). In the future, both parties will jointly promote high-quality in vitro diagnostic products to benefit patients in China and other emerging market countries.
Starting from January 1, 2024, Revvity will exclusively supply Virtue Diagnostics with instruments, reagents and consumables for the TRF Immunoassay Platform EasyCuta Mini, Pre-NAT II nucleic acid extraction system PCR molecular diagnostics analyzer for infectious disease diagnosis (excluding blood bank operations), and Superflex Automatic POCT chemiluminesence Immunoassay analyzer for cardiac and inflammation markers. Virtue Diagnostics has been granted rights to sell the licensed products worldwide, as well as after-sales services. Virtue Diagnostics intends to continue investing in R&D to expand related product lines. Production Localization and registration of licensed products in emerging markets will commence when considered suitable.
As an innovative in vitro diagnostic enterprise, Virtue Diagnostics in 2022 acquired Labtest Diagnostics, the leading Brazilian IVD company, and established production and operational bases in Indonesia. These strategic initiatives mark Virtue Diagnostics officially entering into overseas emerging markets, through deploying diagnostic platforms in biochemistry, chemiluminescence, and molecular technologies.
Mr. Johnson Zhang, Founder & Global CEO of Virtue Diagnostics, stated, “We are delighted to see Virtue Diagnostics and Revvity collaborating once again. This partnership is a significant milestone in aligning our product portfolios and market strategies. For Virtue Diagnostics, this means possessing a more comprehensive technical and product portfolio, which is beneficial for diversifying our product combinations in the domestic market, and facilitating Virtue Diagnostics to achieve global development goals. We look forward to close collaboration with Revvity in delivering cutting-edge products and services more to patients around the world.”
Ms. Nicky Xu, General Manager of Revvity’s Diagnostic Business Unit in China, expressed, “We are pleased to once again join forces with Virtue Diagnostics after our collaboration on clinical mass spectrometry products. Revvity possesses world leading technical R&D capabilities, and Virtue Diagnostics has profound experience in localized operations and market development. This collaboration perfectly aligns our strengths in different areas. In the future, we anticipate further cooperation with Virtue Diagnostics, deepening collaboration and interactions in various fields to achieve seamless integration. This collaboration will not only propel the overall development of the Chinese IVD industry but also have a profound impact on the global diagnostic field. Let us join hands and create a better future together.”
About Virtue Diagnostics:
Founded in 2019, Virtue Diagnostics is an in vitro diagnostic provider committed to platform innovation in emerging markets. We have built a management team with decades of experience in the in vitro diagnostic industry and a global vision, coupled with robust R&D, operation and commercialization capabilities. We set up our industrialization bases in China, Brazil and Indonesia, and R&D centers in Singapore, China and Brazil. We are continuously expanding our global footprint through cooperative R&D, investment, mergers and acquisitions. Focusing on oncology and chronic diseases, Virtue Diagnostics utilizes innovative technology platforms such as clinical mass spectrometry, multiplex immunohistochemistry and molecular diagnostics to expand the China market. Through local capabilities built in emerging countries, Virtue Diagnostics is providing completed diagnostics menu cross biochemistry, chemiluminescence and molecular technologies.
About Revvity:
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. Please visit www.revvity.cn to learn more about Revvity.
